Aileron Therapeutics Announces Late-Breaking Oral Presentation of Non-Clinical Data Demonstrating ALRN-6924 Protected Human Hair Follicles and Their…

Aileron Therapeutics, Inc.

Taxanes, such as paclitaxel and docetaxel, cause severe and often permanent chemotherapy-induced hair loss (alopecia)

New non-clinical data demonstrate proof of principle that ALRN-6924 can temporarily arrest the cell cycle in human scalp hair follicles and their stem cells

ALRN-6924-induced cell cycle arrest protected hair follicles from paclitaxel-induced toxicity and irreversible stem cell damage

Ailerons precision medicine-based approach is designed to selectively protect normal, healthy cells from chemotherapy while ensuring chemotherapy cannot protect cancer cells

Ailerons ongoing non-small cell lung cancer (NSCLC) clinical trial and upcoming breast cancer clinical trial will evaluate ALRN-6924s protection against chemotherapy-induced bone marrow toxicities and other side effects, including alopecia

BOSTON, May 10, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patients lives, today announced a late-breaking oral presentation at the upcoming Society for Investigative Dermatology (SID) Annual Meeting, which will be held May 18 21, 2022 in Portland, Oregon. The presentation will highlight new non-clinical data developed in collaboration with Professor Ralf Paus, M.D., DSc, FRSB and his colleagues at the Dr. Phillip Frost Department of Dermatology & Cutaneous Surgery at the University of Miami Miller School of Medicine. This collaboration has generated promising ex vivo data demonstrating that ALRN-6924 protected human hair follicles and their stem cells from chemotherapy-induced acute and permanent damage. Details of the presentation are as follows:

Title:

ALRN-6924, a dual inhibitor of MDMX and MDM2, protects human scalp hair follicles and their epithelial stem cells from paclitaxel-induced toxicity (LB1018)

Presenter:

Jennifer Gherardini, Ph.D.; Paus Laboratory, University of Miami Miller School of Medicine

Date:

Thursday, May 19th

Time:

8:45 AM 11:15 AM PT

Session:

Late-Breaking Abstract Concurrent Session

Chemotherapy-induced toxicities range from severe and life-threatening to those that impact and diminish patients quality of life, sometimes long after chemotherapy has been completed. These toxicities occur because chemotherapy destroys normal, healthy cells while simultaneously destroying cancer cells, said Manuel Aivado, M.D., Ph.D., President and Chief Executive Officer at Aileron. Previously, we showed chemoprotection against severe bone marrow toxicities in small cell lung cancer patients receiving topotecan and demonstrated in healthy volunteers the mechanism of action cell cycle arrest underlying this chemoprotection benefit. We are excited to now present new data that may suggest ALRN-6924s ability to also protect against chemotherapy-induced hair loss, another devastating chemotherapy-induced side effect for millions of cancer patients.

Dr. Paus commented, These results got us quite excited as they directly follow in the footsteps of our prior work that showed arresting the cell cycle can have a strong protective effect against taxane-induced hair follicle damage. Until our research with ALRN-6924, we had not come across a cell cycle arrest-inducing drug that is in clinical testing for protection of normal cells without protecting cancer cells. Thus, ALRN-6924 invites a very promising and completely novel selective protection approach. In addition, we found that ALRN-6924 may exert some additional benefits that could reduce the risk of long-term damage of human hair follicle stem cells by taxanes.

Story continues

Aileron is currently developing ALRN-6924, a first-in-class MDM2/MDMX dual inhibitor, to selectively protect healthy cells in patients with cancers that harbor p53 mutations to reduce or eliminate chemotherapy-induced side effects while preserving chemotherapys attack on cancer cells. ALRN-6924 is designed to activate p53 in normal cells, which in turn upregulates p21, which pauses cell cycle in normal cells but not in p53-mutated cancer cells. The companys vision is to bring chemoprotection to all patients with p53-mutated cancer regardless of the type of cancer or chemotherapy.

About the Findings

Taxanes, such as paclitaxel and docetaxel, are known to cause severe and often permanent chemotherapy-induced alopecia. Over 90% of patients treated with this chemotherapy class experience alopecia, and approximately 10% (paclitaxel) to 25% (docetaxel) of patients experience permanent alopecia. Dr. Paus and his team previously demonstrated that paclitaxel damages human scalp hair follicles by inducing massive mitotic defects and apoptosis in hair matrix keratinocytes as well as bulge stem cell DNA damage, and that pharmacological induction of transient cell cycle arrest can protect hair follicles and stem cells (Purba et al. EMBO Molecular Medicine 2019). Aileron previously conducted in vitro studies showing that ALRN-6924 protected human fibroblasts in cell culture from multiple chemotherapies, but not p53-mutant breast cancer cells.

In the new non-clinical findings to be presented at the SID meeting, when organ-cultured anagen (i.e., active growth phase) scalp hair follicles from two human donors were pre-treated with ALRN-6924 or vehicle (i.e., placebo), followed by paclitaxel or vehicle, ALRN-6924 significantly increased the number of p21-positive hair matrix keratinocytes and bulge stem cells compared to vehicle or paclitaxel alone, confirming cell cycle arrest ex vivo. Further, pretreatment of paclitaxel-treated human hair follicles with ALRN-6924, led to a reduction in the number of melanin clumps, a marker of hair follicle cytotoxicity and dystrophy, as well as a reduction in apoptosis, pathological mitosis, and DNA damage. Aileron believes that these findings support clinical investigation of ALRN-6924 to prevent both acute and permanent chemotherapy-induced alopecia, in addition to its ongoing evaluation of ALRN-6924 to protect against chemotherapy-induced bone marrow and other toxicities.

About Ailerons Clinical Trials of ALRN-6924

Aileron is on track to initiate a Phase 1b randomized, controlled trial of ALRN-6924 in patients with p53-mutated ER+/HER2- neoadjuvant breast cancer in 2Q 2022. The planned breast cancer trial will evaluate ALRN-6924s protection against chemotherapy-induced bone marrow toxicities, as well as other toxicities, including alopecia, in patients with p53-mutated ER+/HER2- breast cancer treated with a doxorubicin plus cyclophosphamide and docetaxel chemotherapy regimen.

The company is currently enrolling patients in a Phase 1b randomized, double-blind, placebo-controlled trial evaluating ALRN-6924s protection against chemotherapy-induced bone marrow and other toxicities in patients with advanced p53-mutated non-small cell lung cancer undergoing treatment with first-line carboplatin plus pemetrexed with or without immunotherapy. While patients in this trial are monitored for alopecia, historically, only a small percentage of patients treated with carboplatin plus pemetrexed experience acute alopecia. Aileron is on track to report interim results on the first 20 patients enrolled in the NSCLC trial in June 2022 and topline results on 60 patients in 4Q 2022.

About Aileron Therapeutics

Aileron is a clinical stage chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patients lives. ALRN-6924, our first-in-class MDM2/MDMX dual inhibitor, is designed to activate p53, which in turn upregulates p21, a known inhibitor of the cell replication cycle. ALRN-6924 is the only reported chemoprotective agent in clinical development to employ a biomarker strategy, in which we exclusively focus on treating patients with p53-mutated cancers. Our targeted strategy is designed to selectively protect multiple healthy cell types throughout the body from chemotherapy without protecting cancer cells. As a result, healthy cells are spared from chemotherapeutic destruction while chemotherapy continues to kill cancer cells. By reducing or eliminating multiple chemotherapy-induced side effects, ALRN-6924 may improve patients quality of life and help them better tolerate chemotherapy. Enhanced tolerability may result in fewer dose reductions or delays of chemotherapy and the potential for improved efficacy.

Our vision is to bring chemoprotection to all patients with p53-mutated cancers, which represent approximately 50% of cancer patients, regardless of type of cancer or chemotherapy. Visit us at aileronrx.com to learn more.

Forward-Looking Statements

Statements in this press release about Ailerons future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements about the potential of ALRN-6924 as a chemoprotective agent, including its ability to prevent both acute and permanent chemotherapy-induced alopecia, and the Companys strategy and clinical development plans. The words anticipate, believe, continue, could, estimate, expect, intend, may, plan, potential, predict, project, should, target, would and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including whether Ailerons cash resources will be sufficient to fund its continuing operations for the periods anticipated or with respect to the matters anticipated; whether initial results of clinical trials will be indicative of final results of those trials or results obtained in future clinical trials, including trials in different indications; whether ALRN-6924 will advance through the clinical trial process on a timely basis, or at all; whether the results of such trials will be accepted by and warrant submission for approval from the United States Food and Drug Administration or equivalent foreign regulatory agencies; whether ALRN-6924 will receive approval from regulatory agencies on a timely basis or at all or in which territories or indications ALRN-6924 may receive approval; whether, if ALRN-6924 obtains approval, it will be successfully distributed and marketed; what impact the coronavirus pandemic may have on the timing of our clinical development, clinical supply and our operations; and other factors discussed in the Risk Factors section of Ailerons annual report on Form 10-K for the year ended December 31, 2021, filed on March 28, 2022, and risks described in other filings that Aileron may make with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Aileron specifically disclaims any obligation to update any forward-looking statement, whether because of new information, future events or otherwise.

Investor Contact: Stern Investor Relations Alexander Lobo alex.lobo@sternir.com

Media Contact: Liz Melone 617-256-6622

Original post:
Aileron Therapeutics Announces Late-Breaking Oral Presentation of Non-Clinical Data Demonstrating ALRN-6924 Protected Human Hair Follicles and Their...

Stem Cell Technology Helps Identify a Potential Casual Mechanism in Schizophrenia That Could Be Targeted – Brain & Behavior Research Foundation |

New research by a team that included four BBRF grantees has demonstrated the value of studying the causes of complex psychiatric illness by analyzing neurons grown in the laboratory, using stem-cell technology.

In experiments reported in Nature Communications, 2014 BBRF Young Investigator Ian Maze, Ph.D., a Howard Hughes Medical Institute Investigator at the Icahn School of Medicine at Mount Sinai, and 2019 BBRF Young Investigator Lorna A. Farrelly, Ph.D., also at Mount Sinai, and colleagues, used stem cell technology to identify a protein involved in the regulation of gene expression whose inhibition may help to ameliorate abnormalities in neurons that are associated with early pathology in schizophrenia. Adding to the interest of the finding, there is a known drug that can inhibit the protein in question, suggesting a potential future approach to treat or even prevent schizophrenia in some instances.

Developed in the second decade of the 2000s by researchers including BBRF Scientific Council members Ronald McKay, Ph.D., Stewart Anderson, M.D., Fred Gage, Ph.D. and Kristen Brennand, Ph.D., "human induced pluripotent stem cell" (hiPSC) technology involves harmlessly sampling cells (usually skin cells) from an individual and then genetically reprograming these cells to re-develop as other cell types. When reprogrammed as neural cells, these baby cells are grown in culture dishes, and can be brought together with other developing neurons to form "organoids," in which neurons and other cells found in the living brain wire together and form functional networks.

Not only does stem-cell technology enable researchers to generate virtually limitless quantities of live human neurons, overcoming the problem of having to rely on postmortem brain tissue to study brain tissue from psychiatric patients. Just as important, every cell perfectly represents the complex genetics of the patient whose donated skin cells are the basis of the organoid.

This makes hiPSC technology uniquely valuable in the study of illnesses like schizophrenia, in which genetic factors are strongly involved in causation, and pathology in many cases is hypothesized to have its origins in the early development of the braina phase that organoids can recapitulate in the lab.

The team, which included BBRF Scientific Council members Dr. Brennand (who is 2018 BBRF Maltz Prize winner, 2016 Independent Investigator and 2012 Young Investigator) and 2011 BBRF Lieber Prize winner and 2010 and 1998 BBRF Distinguished Investigator Carol A. Tamminga, M.D., induced skin cells sampled from individuals with schizophrenia to re-develop as neurons of the type found in the forebrain. Cells in the forebrain process information from the senses and are involved in thinking, perceiving, producing, and understanding language, as well as controlling motor function.

The team made an important observation in reprogrammed neurons derived from patient samples as these cells were maturing: they detected aberrant patterns of epigenetic activity. Epigenetics refers to molecular processes that affect the way specific genes are expressed in a cell. Every human cell contains an individual's entire genome, and gene-regulating factors, including epigenetic factors, determine when and where in the body or in an organ like the brain specific genes will be activated or repressed, depending upon the biological context.

The abnormal epigenetic pattern the team found is called hyperacetylation. Acetyl molecules are among the epigenetic factors that attach to DNA packaging proteins to encourage or repress gene activation. Hyperacetylation means that there are too many acetyl molecules attaching to bundles of DNA called histones. This causes one or more genes to be abnormally regulated.

The team also identified a specific protein, called BRD4, which, when blocked or repressed in its activity of "reading" the epigenetic state of a given histone, can restore or alleviate the severity of aberrant gene expression caused by hyperacetylation. Experiments indicated that a BRD4 inhibitor might specifically alleviate a kind of aberrant gene expression linked with schizophrenia.

This is exciting because a drug called JQ1 has been shown, in other research, to prevent interactions between proteins like BRD4 and bundled DNA. The drug has been tested in anti-cancer applications, but as the team notes, "the potential of using such inhibitors [of BRD4 and related proteins] to alleviate schizophrenia-related gene expression has remained unexplored."

The team proposes that treatments with JQ1 might "partially rescue" irregularities in gene expression associated with schizophrenia. They say their results warrant further experimental investigation of this possibility.

In addition to Drs. Brennand and Maze, Haitao Li, Ph.D. of Tsinghua University, PRC, was also a senior member of the team.

The rest is here:
Stem Cell Technology Helps Identify a Potential Casual Mechanism in Schizophrenia That Could Be Targeted - Brain & Behavior Research Foundation |

Aspen Neuroscience Announces $147.5 Million Series B Financing, Led by GV, LYFE Capital and Revelation Partners – PR Newswire

Aspen Neuroscience is preparing to study its first autologous cell replacement candidate in Parkinson's disease

GV, LYFE Capital and Revelation Partners co-led the investment round with participation from additional new investors Newton Investment Management, Singapore-based global investor EDBI, LifeForce Capital, Medical Excellence Capital Partners, Mirae Asset Capital, NS Investment and others. As part of the financing, Doug Fisher of Revelation Partners will join the board of directors.

The raise included significant investments from Series A/Seed investment teams including OrbiMed, ARCH Venture Partners, Frazier Life Sciences, Section32 and Alexandria Venture Investments.

"As the leader in autologous cell therapy development, Aspen Neuroscience is preparing to study its first cell replacement candidate in Parkinson's disease," said Damien McDevitt, Ph.D., president and chief executive officer. "This company was founded by a visionary team of scientists and patient advocates, who envisioned a day when personalized cell replacement could be used to target neurodegenerative diseases. We are happy to be aligned with such a prestigious group of founders and investors, having raised more than $220 million since the company's founding, towards our mission to develop transformational medicines for patients with limited treatment options."

The Series B funding will support the planned studies of the company'slead product candidate for Parkinson's disease, ANPD001, including its patient Screening Cohort study and the upcoming Phase 1/2a clinical trial,post-IND submission to FDA.

"This is an important milestone in the field of cell therapy for neurodegenerative diseases and we are immensely proud of this innovative team, who are working to transform the field and to modify the course of Parkinson's disease," said Faheem Hasnain, Aspen Neuroscience chairman.

Aspen is the leading company developing a personalized cell replacement using a patient's own cells, eliminating the need for immunosuppressive therapy. Developed from a simple skin biopsy, each patient's stem cell-derived dopamine neurons will be evaluated for potential effectiveness using proprietary AI-based genomics tools, before being transplanted for clinical use. Aspen Neuroscience's process allows for a reduction in the time and cost of the manufacturing process required to produce a safe, reproducible, and personalized autologous cell therapy. To date, Aspen has performed in vitro and in vivo studies demonstrating that the protocol reliably produces dopamine-releasing neurons when examined both physiologically and functionally.

Dr. McDevitt, continued, "We combine stem cell biology with innovative AI/bioinformatic and manufacturing tools to develop patient-specific approaches. To that end, the Series B financing will also support our R&D pipeline, which includes autologous gene-corrected cells and programs that explore the treatment of other neurological diseases."

About Parkinson's DiseaseParkinson's Disease is the second most common neurodegenerative disease, affecting around one million Americans and greater than ten million people worldwide, with 60,000 people newly diagnosed every year. Even with the current standard of care therapy, patients eventually develop debilitating motor complications due to loss of dopamine neurons in the brain; approximately 50% are lost even before diagnosis. Cell replacement therapy of dopamine neurons has the potential to release dopamine and reconstruct neural networks.

About Aspen NeuroscienceHeadquartered in San Diego, Aspen Neuroscience, Inc. is a development stage, private biotechnology company focused on personalized (autologous) cell therapies. The company is developing induced-pluripotent stem cells (iPSCs) to address diseases with high unmet medical need, beginning with autologous neuron replacement for both sporadic and genetic forms of Parkinson's disease (PD) and extending across the brain and affected organs.

A leading iPSC platform company, Aspen combines stem cell biology with the latest artificial intelligence and genomic approaches to investigate patient-specific, restorative treatments. The company has developed a best-in-class platform to create and characterize pluripotent-derived cell medicines, which includes in-house bioinformatics, manufacturing and QC. For more information and important updates,please visit http://www.aspenneuroscience.com.

SOURCE Aspen Neuroscience , Inc.

Continued here:
Aspen Neuroscience Announces $147.5 Million Series B Financing, Led by GV, LYFE Capital and Revelation Partners - PR Newswire

INFOBAE.COM: Houston doctors and researchers that are making the biggest international impact according to the KOLs list – Most of them are women – PR…

SANTA BARBARA, Calif., May 11, 2022 /PRNewswire/ --The work of Houston doctors and researchers is getting international attention. The most researched areas in Houston after COVID are Oncology, Cardiology, and Endocrinology.

According to the KOLs list, the leading institutions are The University Of Texas MD Anderson, Houston Methodist, Harris Health System, Heart Institute, and Baylor College Of Medicine.

Gender diversity among the top Houston researchers

Ana Gannon, Director of technology of the firm Key Opinion Leaders, commented on the issue "It is not common to see the level of gender diversity we see in Houston in terms of researchers that are creating international impact with their work and findings."

"To give an example, within the group of Houston researchers working on next-generation cancer therapies, such as CAR-T, and whose work is having an international projection, the vast majority of them are women," Mrs. Gannon added.

The analysis prepared by the firm Key Opinion Leaders and available at keyopinionleaders.comquantifies the level of impact of researchers around the world for specific medical concepts like medical conditions, medications, active ingredients, treatments, devices, and more.

What is a "Key Opinion Leader"?

A key opinion leader (KOL) is an expert, thought leader, or influencer who has earned the trust of their peers for an area of knowledge. In healthcare, KOLs play an essential role in shaping the discourse around key issues and helping to drive change within the health system. Patients, physicians, and sometimes even regulatory agencies accept their input while making decisions.

Top Houston Researchers working on next-generation Cancer therapies

According to the KOLs list, some of the Houston researchers whose work on next-generation cancer therapies is getting the most international attention are:

... Please click here to see the other research categories and the full KOLs list on infobae.com.

Amy Mcquade [emailprotected] https://www.youtube.com/watch?v=t32izA3MWrwHow-to-guide for finding KOLs

SOURCE Key Opinion Leaders, LLC

Read more here:
INFOBAE.COM: Houston doctors and researchers that are making the biggest international impact according to the KOLs list - Most of them are women - PR...

Cannabis, heart disease, and a soy-derived supplement that may help – Medical News Today

Researchers are still learning about the health impacts of cannabis. Derivatives of cannabis may have many health benefits. However, researchers are still learning how to balance these positives with potential health risks.

A recent study published in the journal Cell examined the adverse cardiovascular effects of cannabis and found a particular impact on cardiovascular health.

However, the researchers also found that the compound genistein may help decrease these harmful effects.

Cannabis use is becoming increasingly popular, especially for recreational purposes. But researchers are still seeking to discover the full medicinal benefits of cannabis.

The U.S. Centers for Disease Control and Prevention notes that tetrahydrocannabinol (THC) is the compound in cannabis that produces mind alterations and impaired mental functioning. Specifically, the main compound that causes these effects is delta-9-tetrahydrocannabinol (delta-9-THC). In contrast, the cannabidiol (CBD) compound of cannabis doesnt cause this sort of impairment.

Currently, the U.S. Food and Drug Administration (FDA) has approved the use of Epidiolex, which contains CBD. People can use this drug as a seizure treatment. The FDA has also approved the use of two medications with synthetic THC: Marinol and Syndros. Both of these medications can control nausea and stimulate appetite.

However, in addition to the benefits, cannabis has also been linked to health risks. One particular area of interest is the potential association between cannabis and cardiovascular problems.

When asked to comment, Paul Armentano, deputy director for the National Organization for the Reform of Marijuana Laws (NORML), noted that many studies have yielded inconsistent results regarding the impact of cannabis on cardiovascular health. He explained to Medical News Today:

Population-based studies evaluating the potential link between cannabis exposure and cardiovascular risks have, historically, yielded notoriously inconsistent resultsNonetheless, because of the lack of consistent data, NORML has long urged caution with respect to cannabis exposure among those with a history of heart disease or other cardiovascular issues, among other potentially higher-risk populations.

Therefore, more research is needed in this area.

The study in question sought to explore this link. Researchers first examined the association between cannabis use and heart attacks using the U.K. Biobank, the largest prospective cohort study to date, containing genetic and phenotypic data on 500,000 individuals ages 40-69.

Based on the evaluation of this data, cannabis use was associated with a higher risk for heart attack.

The researchers also recruited participants who smoked cannabis recreationally. They found that these participants had higher levels of inflammatory cytokines after smoking a cannabis cigarette, indicating a greater risk for atherosclerosis.

Next, the study authors examined the impact of delta-9-THC on endothelial cells, which are the cells that make up the cardiovascular system. They found that delta-9-THC caused oxidative stress and inflammation, both of which cause harm to the cardiovascular system.

In mice models, they also discovered that delta-9-THC caused vascular dysfunction. Their research indicates that delta-9-THC could damage the cardiovascular system.

To counteract these effects, the researchers tested the compound genistein derived from soybeans. They found that it helped reduce the impact of inflammation and oxidative stress on the cardiovascular system.

They further discovered that genistein helped lessen the severity of atherosclerosis in mouse models.

Dr. Joseph Wu, professor of cardiovascular medicine and of radiology, and the director of the Stanford Cardiovascular Institute, gave the studys highlights to MNT:

Our study shows that marijuana (cannabis) is linked to cardiovascular disease based on the U.K. biobank, stem cell-derived vascular cells, and mouse models. Using machine learning, we also discover a naturally occurring soybean derivative, genistein, that we can be used to block the bad effects of marijuana on the cardiovascular system. Dr. Joseph Wu

The study had several limitations. Firstly, the researchers could not show a causal relationship between cannabis use and heart attacks. They acknowledge the potential for flaws in the data from the U.K. Biobank cohort.

The study also used mice models, so caution must be exercised when applying any results to people.

Armentano also said that the study may fall short in terms of consistency of research in the area.

This latest paper is simply the latest in a long line of inconsistent results results that likely vary based on how well investigators do or do not control for potential confounding variables and behaviors among subjects.

However, he pointed out that the researchers theory, based on results from their mice studies, was that it could be due to cannabinoids triggering inflammation of the blood vessels and thus atherosclerosis is inconsistent with human observational studies.

Nevertheless, the results indicated that genistein could help mitigate the potentially harmful effects of cannabis while maintaining some of its beneficial effects.

Study authors wrote that [g]enistein, a soybean isoflavone, blocks harmful cardiovascular effects of [delta-9-THC] while reserving clinically useful effects such as sedation and analgesia.

Study author Joseph Wu further elaborated to MNT about the direction of further research in this area:

While we have shown that genistein can block the adverse effects of marijuana on the cardiovascular system using preclinical models, we need to do a randomized clinical trial to test its safety and effectiveness in humans.

Genistein might also be a new lead compound that will lead to the development of new drugs that can treat cardiovascular disease, Wu added.

Go here to read the rest:
Cannabis, heart disease, and a soy-derived supplement that may help - Medical News Today

Stem Cell Assay Market Size In 2022 with Top Countries Data : What is the CAGR scope of the Stem Cell Assay market in the forthcoming period? | Latest…

Stem Cell Assay Market In 2022 (Growth Insights) : The high demand for Stem Cell Assay which is used in various applications such as Regenerative Medicine & Therapy Development, Drug Discovery and Development, Clinical Research and Others will drive the Stem Cell Assay market.

According to this latest study, In 2022 the growth of Stem Cell Assay Market will have significant change from previous year. Over the next five years the Stem Cell Assay Market will register a magnificent spike in CAGR in terms of revenue, In this study, 2021 has been considered as the base year and 2022 to 2026 as the forecast period to estimate the market size for Stem Cell Assay.

Global Stem Cell Assay Market 2022 Research Report provides key analysis on the market status of the Stem Cell Assay manufacturers with best facts and figures, meaning, definition, SWOT analysis, expert opinions and the latest developments across the globe. The Report also calculate the market size, Stem Cell Assay Sales, Price, Revenue, Gross Margin and Market Share, cost structure and growth rate. The report considers the revenue generated from the sales of This Report and technologies by various application segments and Browse Market data Tables and Figures spread through 110 Pages and in-depth TOC on Stem Cell Assay Market.

The Impact of COVID-19 on the global Stem Cell Assay market:

Sudden outbreak of the COVID-19 pandemic had led to the implementation of stringent lockdown regulations across several nations resulting in disruptions in import and export activities of Stem Cell Assay.

In COVID-19 outbreak, Chapter 2.2 of this report provides an analysis of the impact of COVID-19 on the global economy and the Stem Cell Assay industry, Chapter 3.7 covers the analysis of the impact of COVID-19 from the perspective of the industry chain. In addition, chapters 7-11 consider the impact of COVID-19 on the regional economy.

Final Report will add the analysis of the impact of COVID-19 on this industry.

TO UNDERSTAND HOW COVID-19 IMPACT IS COVERED IN THIS REPORT REQUEST SAMPLE

Global Stem Cell Assay Market Development Strategy Pre and Post COVID-19, by Corporate Strategy Analysis, Landscape, Type, Application, and Leading 20 Countries covers and analyzes the potential of the global Stem Cell Assay industry, providing statistical information about market dynamics, growth factors, major challenges, PEST analysis and market entry strategy Analysis, opportunities and forecasts. The biggest highlight of the report is to provide companies in the industry with a strategic analysis of the impact of COVID-19. At the same time, this report analyzed the market of leading 20 countries and introduce the market potential of these countries.

Get a Sample PDF of report https://www.360researchreports.com/enquiry/request-sample/18676462

Top Key Players Operative in Stem Cell Assay Market

Key Insights In Stem Cell Assay Market?

The Global Stem Cell Assay market is anticipated to rise at a considerable rate during the forecast period, between 2021 and 2026. In 2021, the market is growing at a steady rate and with the rising adoption of strategies by key players; the market is expected to rise over the projected horizon.

Projected Market size & Growth rate (CAGR) of Stem Cell Assay market:

In 2020, the global Stem Cell Assay market size was USD million and it is expected to reach USD million by the end of 2026, with a magnificent compound annual growth rate between 2021 and 2026.

Analysis Of Stem Cell Assay Market In 2022:

The market in North America is expected to grow considerably during the forecast period. The high adoption of advanced technology and the presence of large players in this region are likely to create ample growth opportunities for the market. The market in North America is expected to hold the largest market share, whereas the APAC region is projected to provide significant opportunities in this market and is expected to grow at the highest CAGR during the forecast period.

Despite the presence of intense competition, due to the global recovery trend is clear, investors are still optimistic about this area, and it will still be more new investments entering the field in the future.

Driving Factors for the growth of the Stem Cell Assay Market:

The Increasing use of Stem Cell Assay in Regenerative Medicine & Therapy Development, Drug Discovery and Development, Clinical Research is driving the growth of the Stem Cell Assay market across the globe.

Scope Of Stem Cell Assay Market:

Stem Cell Assay market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Stem Cell Assay market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.

Get a Sample Copy of the Stem Cell Assay Market Report 2021

Report further studies the market development status and future Stem Cell Assay Market trend across the world. Also, it splits Stem Cell Assay market Segmentation by Type and by Applications to fully and deeply research and reveal market profile and prospects.

Leading segment based on product type?

Applications of Stem Cell Assay Market?

Chapters 7-26 focus on the regional market. We have selected the most representative 20 countriesfrom197 countries in the world and conducted a detailed analysis and overview of the market development of these countries.

This Stem Cell Assay Market Research/Analysis Report Contains Answers to your following Questions

Inquire more and share questions if any before the purchase on this report at https://www.360researchreports.com/enquiry/pre-order-enquiry/18676462

Major Points from Table of Contents

Global Stem Cell Assay Market Research Report 2021-2026, by Manufacturers, Regions, Types and Applications

1 Introduction 1.1 Objective of the Study 1.2 Definition of the Market 1.3 Market Scope 1.3.1 Market Segment by Type, Application and Marketing Channel 1.3.2 Major Regions Covered (North America, Europe, Asia Pacific, Mid East & Africa) 1.4 Years Considered for the Study (2015-2026) 1.5 Currency Considered (U.S. Dollar) 1.6 Stakeholders

2 Key Findings of the Study

3 Market Dynamics 3.1 Driving Factors for this Market 3.2 Factors Challenging the Market 3.3 Opportunities of the Global Stem Cell Assay Market (Regions, Growing/Emerging Downstream Market Analysis) 3.4 Technological and Market Developments in the Stem Cell Assay Market 3.5 Industry News by Region 3.6 Regulatory Scenario by Region/Country 3.7 Market Investment Scenario Strategic Recommendations Analysis

4 Value Chain of the Stem Cell Assay Market

4.1 Value Chain Status 4.2 Upstream Raw Material Analysis 4.3 Midstream Major Company Analysis (by Manufacturing Base, by Product Type) 4.4 Distributors/Traders 4.5 Downstream Major Customer Analysis (by Region)

Get a Sample Copy of the Stem Cell Assay Market Report 2021

5 Global Stem Cell Assay Market-Segmentation by Type 6 Global Stem Cell Assay Market-Segmentation by Application

7 Global Stem Cell Assay Market-Segmentation by Marketing Channel 7.1 Traditional Marketing Channel (Offline) 7.2 Online Channel

8 Competitive Intelligence Company Profiles

9 Global Stem Cell Assay Market-Segmentation by Geography

9.1 North America 9.2 Europe 9.3 Asia-Pacific 9.4 Latin America

9.5 Middle East & Africa

10 Future Forecast of the Global Stem Cell Assay Market from 2021-2026

10.1 Future Forecast of the Global Stem Cell Assay Market from 2021-2026 Segment by Region 10.2 Global Stem Cell Assay Production and Growth Rate Forecast by Type (2021-2026) 10.3 Global Stem Cell Assay Consumption and Growth Rate Forecast by Application (2021-2026)

11 Appendix 11.1 Methodology 12.2 Research Data Source

Continued.

Purchase this report (Price 4000 USD for a single-user license) https://www.360researchreports.com/purchase/18676462

About Us:

360 Research Reports is the credible source for gaining the market reports that will provide you with the lead your business needs. At 360 Research Reports, our objective is providing a platform for many top-notch market research firms worldwide to publish their research reports, as well as helping the decision makers in finding most suitable market research solutions under one roof. Our aim is to provide the best solution that matches the exact customer requirements. This drives us to provide you with custom or syndicated research reports.

Contact Us: Web : https://360researchreports.com Email: [emailprotected] Organization: 360 Research Reports Phone: +44 20 3239 8187/ +14242530807

For More Related Reports Click Here :

Anticancer Drugs Market Size In 2022 : 3.7% CAGR with Top Countries Data, Which product segment is expected to garner highest traction within the Anticancer Drugs Industry? | In-depth 95 Pages Report

Medical Batteries Market Size In 2022 : 2.6% CAGR with Top Countries Data, What is estimated to be the valuation of the global Medical Batteries Industry by 2026? | In-depth 99 Pages Report

Smoke and Carbon Monoxide Alarm Market Size In 2022 : 6.8% CAGR with Top Countries Data, What is estimated to be the valuation of the global Smoke and Carbon Monoxide Alarm Industry by 2026? | In-depth 119 Pages Report

Read the original here:
Stem Cell Assay Market Size In 2022 with Top Countries Data : What is the CAGR scope of the Stem Cell Assay market in the forthcoming period? | Latest...

Technologies and tools to decipher cell surface glycans as onco-developmental and stem cell markers of man and mouse – Imperial College London

Joint Oncology/IRDB Imperial Seminar Series, Thursday 24.03.22 @ 13.30, hosted by Dr David MacIntyre.

We are delighted to have Professor Ten Feizi, Director of The Glycosciences Laboratory, Faculty of Medicine, Department of Metabolism, Digestion and Reproduction at Imperial College.

Professor Feizi gained her MB BS in 1961 and MD in 1969 at the Royal Free Hospital Medical School. Thereafter, she held fellowships from MRC and US Arthritis Foundation as guest investigator in the laboratories of Richard Krause and Henry Kunkel at Rockefeller University, and Elvin A Kabat at Columbia Medical Center in New York.

In 1985, Ten Feizi and colleagues introduced the innovative neoglycolipid (NGL) technology for linking a glycan sequence to a lipid molecule as a means of immobilization on matrices and probing for binding by diverse glycan recognition systems. In 2002, this became the basis of the first glycoarray system designed to encompass entire glycomes. This is currently still the most diverse glycoarray system in the world, revolutionizing the molecular dissection of glycan-recognition systems in health, in infectious and inflammatory disorders and cancer. Notable among the assignments are the host cell attachment sites for simian virus 40 (SV40),Toxoplasma gondiiand the pandemic A(H1N1) 2009 influenza virus; elucidation of the structures of F77, the elusive prostate cancer antigen; and R10G a marker of induced human pluripotent stem cells.

More here:
Technologies and tools to decipher cell surface glycans as onco-developmental and stem cell markers of man and mouse - Imperial College London

Visionary Progress | The UCSB Current – The UCSB Current

A retinal stem cell patch developed through a collaboration of researchers at UC Santa Barbara, University of Southern California and California Institute of Technology continues to make progress in its bid to secure approval from the Food and Drug Administration. The latest milestone? Results finding that after two years, not only can the implant survive, but also it does not elicit clinically detectable inflammation or signs of immune rejection, even without long-term immunosuppression.

What really makes us excited is that there is some strong evidence to show that the cells are still there two years after implantation and theyre still functional, said Mohamed Faynus, a graduate student researcher in the lab of stem cell biologist Dennis O. Clegg, and a co-author on a paper published in the journal Stem Cell Reports. This is pretty important, because if the goal is to treat blindness, we want to make sure that the retinal pigment epithelium cells that we put in there are still doing the job theyre supposed to.

A treatment in development since 2013, the California Project to Cure Blindness Retinal Pigment Epithelium 1 (CPCB-RPE1) patch consists of a monolayer of human stem cell-derived RPE cells cultured on an ultrathin membrane of biologically inert parylene. The goal for this patch is to replace deteriorating cells in the retinas of those who have age-related macular degeneration, one of the leading causes of blindness worldwide for people over 50. The condition affects the macula the part of the retina responsible for central vision. People with AMD experience distortions and loss of vision when looking straight ahead.

The researchers have made strides with the patch since its inception, guiding it through clinical trials for use with the dry form of AMD. If the implant works, the new cells should take up the functions of the old ones, and slow down or prevent further deterioration. In the best-case scenario, they could restore some lost vision.

The first sets of trials concentrated on establishing the safety of the patch and collecting any data on its effectiveness. The group, in a one-year follow-up published last year in the journal Translational Vision Science & Technology, concluded the outpatient procedure they were developing to implant the patch could be performed routinely and that the patch was well-tolerated in individuals with advanced dry AMD. Early results were promising: Of the 15 patients in the initial cohort, four demonstrated improved vision in the treated eye, while five experienced a stabilization of their vision. Visual acuity continued to decline in the remaining six, and the researchers are working to understand why.

Having implanted the patches in live volunteers, however, the researchers no longer had a direct means for assessing the patches function and any changes in the longer term.

Its a lot more difficult and complicated to do that a clinical trial setting, Faynus said. But we can figure things out by proxy if something is working. So for example, if a patients vision was getting worse and is now getting better, thats worth noting.

But the team had other questions that couldnt necessarily be answered by proxy. Had the cells maintained their identity and thus, their function? Was the patch still in place and were the donor cells surviving? Were there any signs of immune rejection, a common and serious concern for any patient receiving an implant? If they could answer these questions, they would not only be able to take next steps with the patch, they would gain significant knowledge in general for the field of regenerative medicine.

Thanks to the generosity of one patient in the trials, the group would get their chance to find out. Named Subject 125, she passed away at the age of 84 from pneumonia two years after receiving the implant, leaving her eyes and a rare opportunity for the team to check the progress of their patch.

We are very grateful to the brave patients who volunteered in our clinical trial, said Clegg, who holds the Wilcox Family Chair in Biomedicine. Without them, we could not advance the science into what could be an effective therapy for millions of people.

A Key Test To address their questions, the team had to first identify the cells in the general area of the patch.

Now that we had these sections of tissue, how do we demonstrate that the cells on the membrane were RPE cells? Faynus said. That was one of our key questions. Beyond that, they had to identify whether the cells were from the donor or the recipient, and whether they were functional.

Through a careful process of staining and immunoreactivity testing, the team determined that the cells were in fact RPE donor cells, confirming that the cells on the patch hadnt migrated and that the cells were oriented in the optimal, polarized position a sign that they had maintained a healthy, functional form, according to Faynus.

The whole point of us implanting the cells was for them to perform the many functions that RPE cells do, Faynus said. One of those functions in particular is the breakdown of debris and the recycling of vital cellular material.

Every day you open your eyes, and light gets inside the eye, which triggers a whole cascade of events, Faynus explained. One of these being the shedding of photoreceptor outer segments. Without the constant recycling of this material conducted by the RPE cells, he continued, it is thought that proteins and lipids accumulate, forming deposits called drusen, a hallmark of AMD.

In addition, the team found that after two years, the presence of the patch hadnt triggered other conditions associated with implantation, such as the aggressive formation of new blood vessels or scar tissue that could cause a detachment of the retina. Importantly, they also found no clinical sign of the inflammation that can indicate an immune response to the foreign cells even after the patient was taken off immunosuppressants two months post-implantation.

This is the first study of its kind and it indicates that the implanted RPE cells can survive and function, even in what could be a toxic environment of a diseased eye, Clegg said.

Having passed the initial phase of trials, the team is now gearing up to begin Phase 2, which more specifically assesses the effectiveness of the patch. They have also made improvements to the shelf life of the patch, a technological advance they document in the journal Nature. In it, they describe a cryopreservation process that simplifies storage and transport of the cultured cells.

Cryopreservation of the therapy significantly extends the products shelf-life and allows us to ship the implant on demand all over the world, thus making it more accessible to patients across the globe, said Britney Pennington, a research scientist in the Clegg Lab, and lead author of the Nature paper.

Looking to the future, the Clegg Lab and colleagues are exploring combining multiple cell types on the patch.

AMD progresses through several stages, Faynus explained. When the RPE cells degenerate, he continued, the photoreceptors and varying other retinal cells that are supported by the RPE quickly follow suit. To treat patients at varying stages of the disease, we need to consider the remaining cell types. If we can create composite implants that support many of the impacted cells, we can hopefully rescue a patients vision despite the severity of the disease.

View post:
Visionary Progress | The UCSB Current - The UCSB Current

The Top Colleges To Study Medicine In India – CEOWORLD magazine

The concept of Medicine has been in India for a long time. Born in Varanasi in 1200, Sushruta is considered the Father of Surgery. His treatise, the Sushruta Samhita, is said to be the foundational text of Ayurveda. Fast forward a few centuries, India has made enough progress to keep up with the times. Youll find some of the worlds best medical colleges in India. Medical colleges in India are famed for the quality of their faculty, facilities, and research infrastructure.

The top colleges to study Medicine in India are:

the worlds first reconstructive surgery for leprosy (1948) the first successful open-heart surgery in India (1961) the first kidney transplant in India (1971) the first bone marrow transplantation in India (1986) and the first successful ABO-incompatible kidney transplant in India (2009)

Notable alumni: Ajit Varki co-director of the Glycobiology Research and Training Center at the University of California Mahendra Bhandari Padma Shri awardee who made substantial contributions to urology, robotic surgery, and medical ethics

Notable alumni: Brian J.G. Pereira CEO of Visterra, Inc. Bhupathiraju Somaraju Cardiologist and Padma Shri awardee

Notable alumni: Maharaj Kishan Bhan Pediatrician and Padma Bhushan recipient Soumya Swaminathan Chief Scientist at the WHO

Read the original post:
The Top Colleges To Study Medicine In India - CEOWORLD magazine

MS in Stem Cell Biology and Regenerative Medicine

Discover the future of medicine

The Master of Science degree program invites you to chart the course for the medicine of the futureregenerative medicine. This is one of the first masters programs in stem cell biology and regenerative medicine in the United States.

Our one-year program offers courses in cutting-edge biomedical science, including developmental biology, human embryology, regenerative medicine, and the translational and therapeutic aspects of stem cell technology. The program also provides practical hands-on laboratory experience with the growth and differentiation of stem cells. Although not required, students are encouraged to engage in laboratory research during the year, with one of the 80+ lab groups that constitute USC Stem Cell. At the completion of the first year, students may informally continue to conduct research in their labs after receiving the MS diploma, or can petition to continue research with a guided and structured second research year culminating in a capstone thesis project.

After completing this program, you will be poised to apply to medical or PhD programs, enter the growing stem cell pharmaceutical domain, or engage in other academic, clinical or business efforts. You will possess a unique understanding of how the bodys own developmental and repair mechanisms can restore damaged cells, tissues and organsproviding new opportunities to treat conditions ranging from blindness to cancer, from organ failure to HIV/AIDS.

To apply, visit gradadm.usc.edu.

Please note that the application portal for Fall 2022 will open October 15th, 2021. The deadline to apply will be April 1st, 2022.

For questions, e-mail us at scrm@usc.edu or call (323) 865 1266.

Originally posted here:
MS in Stem Cell Biology and Regenerative Medicine